Scroll for more

SCIENCE & INNOVATION

 

Investigator Form

The information provided via this form will be uploaded into Sucampo’ s Investigator database. A Sucampo representative will contact your site should we have an opportunity that matches the information you entered.

 
 

Add Personnel

Title*

First Name*

Last Name*

Email*

Telephone*

Role*

Speciality / Therapeutic Area* (Select all that apply)

 Anesthesiology Cardiovascular Dermatology Emergency Endocrinology/Diabetes Gastroenterology Gene Therapy Geriatrics Hematology Immunology/Allergy Infectious Disease Intensive Care Internal Medicine Musculoskeletal Nephrology Neurology Nuclear Medicine Obstetrics/Gynecology Oncology Ophthalmology Pediatrics Primary Care Psychiatry Pulmonary/Respiratory Rheumatology Surgery - Cardiothoracic Surgery - General/Other Surgery - Neurosurgery Surgery - Orthopedic Surgery - Otolaryngology Transplant Urology Vaccine Other

If other please specifiy*

Site Type*

Site Name* (Enter company name if not a site)

Site Short Name* (e.g. NIH or N/A, if not applicable)

Primary Address*

Address 2

Address 3

Address 4

City*

Province / State / County*

Post / ZIP Code

Country*

Comments

Upload Documents (CVs, Site Brochure, etc.)
Format: pdf|txt|xls|xlsx|doc|docx. Limit 10mb.

To add more personnel, check this box and submit the form.

Add Personnel 

* Please enter all required fields

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.